Months 0-6: Clinical product synthesis and testing
Activities
- GMP synthesis
- Stability
- Toxicology
- Formulation
Output
- IL-2 recombinant vaccinia virus
and melanoma cell lysates
Months 6-12: Pre-Phase I development
Activities
- Expansion of IP
- Animal model
- Phase I clinical trial
Output
- Other cancer and uses
- Phase I
- Immunotherapeutic vaccine
Months 12-24: Initiation and completion of Phase I
Activities
- Clinical development of
MelVac platform
Output
- Licensing of MelVac to strategic partner
- Continued development of combination therapy
Overall development
Activities
- Combination Multicenter trials
- Expanded IP testing autologous trial
Output
- Phase I/ II trial
- Autologous and allogeneic vaccine
- efficacy testing